Aptevo Therapeutics Inc. (NASDAQ: APVO ) announced that its lead candidate mipletamig achieved a 93% clinical benefit rate when administered as a triplet therapy to frontline acute myeloid leukemia patients carrying TP53 mutations.
The clinical-stage biotechnology firm develops multispecific immuno-oncology therapeutics to target high-risk patient groups that have historically demonstrated poor responses to existing medical treatments.
Strong Remission Outcomes In High-Risk AML
In the evaluation, 13 out of 14 evaluable TP53-mutated subjects receiving mipletamig alongside venetoclax and azacitidine experienced clinical benefit, incorporating two participants from a prior dose-expansion trial .
Overall, 11 patients—representing 79% of the cohort—achieved complete remission or complete remission with incomplete hematologic recovery, with nine of those individuals reaching full complete remission.
Read Next Trading IdeasCuris Gains As Blood Cancer Drug Progresses, December Readout in Focus
Curis gained attention after positive emavusertib data as analyst raised its price target to $43 and highlighted upcoming trial catalysts.
2 min read Read this articleThe 79% response rate observed with the mipletamig triplet compares favorably to a published 41% composite remission rate for the venetoclax and azacitidine combination alone in treatment-naïve, poor-risk cytogenetic patients .
RAINIER Trial Roadmap And Unique Mechanism
Aptevo is currently conducting the RAINIER study, an open-label, multicenter Phase 1b/2 dose-optimization trial examining adults newly diagnosed with acute myeloid leukemia who cannot undergo high- intensity induction chemotherapy .
TrendingManagement expects to complete the dose optimization portion across sequential 28-day treatment cycles by year-end, with regulatory meetings planned for the first half of 2027 to set future milestones.
The wholly owned lead candidate redirects a patient’s immune system by binding T cells to CD123-expressing leukemic cells and stem cells to promote cancer destruction .
Additionally, mipletamig employs a CRIS-7-derived CD3-binding pathway specifically designed to minimize the likelihood and severity of cytokine release syndrome, distinguishing the candidate from competing therapeutic options.
APVO Stock Price Activity: Aptevo Therapeutics shares were down 22% to $2.02 at the time of publication on Thursday, according to Benzinga Pro data .
Read Next MarketsGreg Abel Dismisses Rising Bond Yields as 'Relatively Modest,' Berkshire Hathaway Eyes Bigger Stakes in Japan's Trading Houses: Report
Berkshire Hathaway CEO Greg Abel eyes bigger Japan stakes as rising bond yields remain manageable, deepening the company’s Japan bet.
3 min read Read this articleImage via Shutterstock/ Yomal2233
Market News and Data brought to you by Benzinga APIs© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here .
Posted In: Trading Ideas Movers News General Biotech Health Care Why It's Moving Retail Investor Stocks